 BEDMER, N.J.--BUSINESS WIRE--- TYME--Tyme Technologies, Inc. NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of 2.50 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offer 